AIM ImmunoTech says Ampligen data supports synergistic potential with checkpoint blockade therapies

AIM ImmunoTech Inc (NYSE:AIM) CEO Tom Equels provided a summary of positive clinical data supporting the synergistic potential of its flagship drug Ampligen (rintatolimod) with checkpoint blockade therapies. Ampligen is the company’s dsRNA drug being developed to fight cancers. It has shown synergy with checkpoint inhibitors, including increasing survival rates and efficacy, in the treatment of animal tumors when used with checkpoint blockade therapies.